Clinical Trial Update: Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma [Phase 3]

View source ↗

Summary

Phase 3 long-term safety update of tezepelumab in Japanese patients with inadequately controlled severe asthma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Severe Asthma | Phase 3 | Status: COMPLETED | Results posted: 2022-06-01